Hearing dogs for people with severe and profound hearing loss: a wait-list design randomised controlled trial investigating their effectiveness and cost-effectiveness

Table 5 Cost-effectiveness analysis: descriptive statistics and results

Costing scenario^a	Trial arm				δ^QALY		δ^COST		ICER	Net health benefit (NHB)
	Hearing dog		Wait-list		δ^QALY		δ^COST			λ = £15,000 per QALY	λ = £20,000 per QALY	λ = £30,000 per QALY
	QALYs	Costs (£)	QALYs	Costs (£)	Obs	Coeff	Obs	Coeff		λ = £15,000 per QALY	λ = £20,000 per QALY	λ = £30,000 per QALY
Multiple imputation analysis for the whole trial period
Excluded	1.300	3909	1.256	4407	165	0.012	165	− 260	Dominant	0.029	0.025	0.021
Included	1.300	7123	1.256	4407	165	0.012	165	2954***	242,912	− 0.185	− 0.136	− 0.086
Multiple imputation analysis for the active intervention period
Excluded	0.372	911	0.353	1206	165	0.014	165	− 291	Dominant	0.034	0.029	0.024
Included	0.372	4125	0.353	1206	165	0.014	165	2,954***	203,959	− 0.182	− 0.133	− 0.084

Key: δ adjusted mean difference, λ opportunity cost threshold, Obs number of observations used to estimate δ, Coeff estimated coefficient 1, ICER incremental cost-effectiveness ratio
^a Refers to two scenarios used for each analysis: costs of providing a hearing dog excluded (i.e. borne by HDfDP charity: the current situation), or included in costs to public sector (health and social care)
*** p value = 0.01

ISSN: 1745-6215